Stem Cell-Food and Drug Administration (FDA) part 1

Stem cell 4

 

Assessment of reasonable

To determine whether it is reasonable to grant permission for a clinical trial to proceed, FDA evaluates potential risk based on results derived from analytical assessment of product characteristics as well as preclinical proof-of-concept and safety testing, which,  collectively, are considered within the context of a proposed clinical study

About azaleaazelia

A nice person... :)
This entry was posted in Tak Berkategori. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s